Redwood City, Calif.- based Dextera, formerly known as Cardica, agreed to the buyout in December 2017. The consummation Feb. 20 saw Dextera receive $13.6 million; another $2 million went into two-year escrow, $900,000 went to repay a loan from Aesculap and the balance was used to pay off contracts and leases and to settle closing expenses, according to a regulatory filing.
Aesculap said it plans to oversee operations in Redwood City, keeping Dextera’s products on the market as it looks to expand its footprint in the cardio-thoracic surgery market.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!